Hence, Jagged1 can be a critical therapeutic target to halt aggressive tumour progression [58], and targeting Jagged1 specifically, as recently attempted [59], can mitigate the side effects of targeting the entire Notch pathway by inhibiting NICD [60]. Here, JAG1 is linked to neoplasm.